|
| Monday, December 18, 2017 |
|
|
Eisai Launches Educational Materials for Understanding Dementia |
| Eisai Co., Ltd. announced that it has created educational materials for understanding dementia and thinking about what one can do for elementary and secondary school students, and has commenced marketing these materials primarily to local governments, educational institutions as well as medical and nursing care professionals from today. more info >> |
|
| Wednesday, December 13, 2017 |
|
|
Eisai's Aricept Approved for Additional Indication of Severe Alzheimer's Disease in China |
| Eisai Co., Ltd. announced today that Aricept (donepezil hydrochloride) has been approved for the additional indication of severe Alzheimer's disease in China. Aricept is the first Alzheimer's disease treatment with a broad indication that covers mild to severe Alzheimer's disease in China. more info >> |
|
| Friday, December 8, 2017 |
|
|
Eisai: Updated Analysis of Phase Ib/II Study of Eribulin and Pembrolizumab Combination Regimen |
| Eisai Co., Ltd. announced today that a presentation on the updated analysis of a global Phase Ib/II clinical study of its in-house discovered and developed anticancer agent eribulin mesylate in combination with the anti-PD-1 therapy pembrolizumab developed by Merck & Co., Inc. more info >> |
|
| Wednesday, December 6, 2017 |
|
|
Eisai Submits Application for Expanded Indication Covering Hepatocellular Carcinoma for Anticancer Agent Lenvima in Taiwan |
| Eisai Co., Ltd. announced that it has submitted an application for its in-house discovered and developed anticancer agent lenvatinib mesylate (product names: Lenvima/Kisplyx, product name in Taiwan: "Lenvima") for an additional indication for use in the treatment of hepatocellular carcinoma (HCC) in Taiwan. more info >> |
|
| Thursday, November 30, 2017 |
|
|
Eisai's Resubmitted NDA for Anticancer Agent Halaven Accepted in China |
| Eisai Co., Ltd. announced today that the China Food and Drug Administration (CFDA) has accepted for review the resubmitted New Drug Application (NDA) for Eisai's anticancer agent eribulin mesylate (eribulin, product name: Halaven). more info >> |
|
| Friday, November 24, 2017 |
|
|
Eisai to Present Latest Data on Perampanel and Rufinamide at 71st American Epilepsy Society Annual Meeting |
| Eisai Co., Ltd. announced today that the latest data on its antiepileptic drugs (AED) perampanel and rufinamide will be presented at the 71st American Epilepsy Society (AES) Annual Meeting to be held from December 1 to 5, 2017 in Washington D.C. in the United States. more info >> |
|
| Monday, November 20, 2017 |
|
|
Eisai Receives IT Business Award for Medication Administration Support Device e-OKUSURI-SAN |
| Eisai Co., Ltd. has announced that it received an "IT Business Award" for its medication administration support device e-OKUSURI-SAN at the fiscal 2017 (35th) IT Awards held by the Japan Institute of Information Technology (JiIT). more info >> |
|
|
Eisai: Antiepileptic Drug Fycompa Regularly Available Again in Germany from December |
| Eisai Co., Ltd. has announced that its German sales company Eisai GmbH and the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) have agreed on a reimbursement price for Eisai's antiepileptic drug (AED) Fycompa (perampanel). more info >> |
|
| Monday, November 6, 2017 |
|
|
New Data From Long-Term Extension of Phase 1B Study of Investigational Alzheimer's Disease Treatment Aducanumab Presented at 10th Clinical Trials on Alzheimer's Disease |
| Eisai Co., Ltd. announced today that Biogen Inc. (Nasdaq: BIIB) presented new data from the long-term extension (LTE) of its ongoing Phase 1b study of aducanumab, an investigational treatment for Alzheimer's disease at the 10th Clinical Trials on Alzheimer's Disease (CTAD) meeting, Boston, Massachusetts, United States, from November 1 to 4. more info >> |
|
| Tuesday, October 31, 2017 |
|
|
Eisai's New Drug Application of Anticancer Agent Lenvatinib for Hepatocellular Carcinoma Accepted in China |
| Eisai Co., Ltd. announced that the China Food and Drug Administration (CFDA) has accepted for review a New Drug Application (NDA) submitted for Eisai's in-house discovered and developed anticancer agent lenvatinib mesylate for use in the treatment of hepatocellular carcinoma (HCC) in China. more info >> |
|
|
|
